As you may recall, I think PTLA is a loser company. I’ve already questioned the credibility of the company’s phase-3 program for Betrixaban, and the $100M raise makes it pretty clear that PTLA will be going it alone for both Betrixaban and PRT4445.
Under the circumstances, it’s reasonable to inquire why BMY/PFE, JNJ/Bayer, and Daiichi Sankyo haven’t done more than ink cashless, non-exclusive arrangements to supply their FXa inhibitors for phase-2 testing with PRT4445.
Two possible explanations: i) the Big Pharma science staffers aren’t convinced that PRT4445 is a one-of-a-kind FXa antidote; and ii) the Big Pharma marketing staffers think giving too much credibility to an antidote sends the wrong message to the docs who are prescribing their anticoagulants.
Market Data 
Markets 
AI
